Crinetics Q2 2026: PALSONIFY Revenue Jumps to $24M, Guidance Pulled Ahead of Vertex Buyout
CRNX has more than doubled off its 52-week low of $25.83.
Summary
Crinetics reported strong Q2 2026 results with PALSONIFY revenue surging to $24 million, but withdrew guidance and canceled its earnings call as the $10 billion Vertex acquisition nears closing.
Key Events · Earnings and Guidance · CRNX
-
PALSONIFY Revenue More Than Doubles
Net product revenue reached $24.0 million in Q2 2026, up from $10.3 million in Q1 2026, with 245 enrollment forms and 385 unique prescribers.
-
Guidance Withdrawn, No Call
Crinetics withdrew all prior guidance and will not host an earnings call, citing the pending acquisition by Vertex.
-
Vertex Acquisition on Track
The $85/share all-cash deal, valued at $10 billion, is expected to close in Q3 2026, subject to stockholder and regulatory approvals.
-
Atumelnant Gets Rare Pediatric Disease Designation
The FDA granted RPDD to atumelnant for classic congenital adrenal hyperplasia, potentially adding a priority review voucher upon approval.
Analysis · CRNX · Life Sciences
Crinetics reported Q2 2026 revenue of $25.1 million, driven by $24 million in PALSONIFY sales — more than double the prior quarter. The company withdrew all guidance and canceled its earnings call, citing the pending $10 billion acquisition by Vertex at $85 per share. With $1.2 billion in cash and a deal expected to close in Q3 2026, the standalone financial trajectory is now secondary to the merger outcome. The rare pediatric disease designation for atumelnant adds pipeline optionality but is unlikely to alter the acquisition calculus.
At the time of this filing, CRNX was trading at $83.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.9B. The 52-week trading range was $25.83 to $84.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.